Bruno Vanderlinden
Overview
Explore the profile of Bruno Vanderlinden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Danieli R, Mileva M, Marin G, Kristanto P, Delbart W, Vanderlinden B, et al.
EJNMMI Res
. 2024 Nov;
14(1):110.
PMID: 39557730
Background: Peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-DOTA-TATE has emerged as a promising treatment for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Its treatment protocol is currently standardised for all patients, resulting in...
2.
Chan D, Hayes A, Karfis I, Conner A, Mileva M, Bernard E, et al.
J Nucl Med
. 2024 Jan;
65(2):185-191.
PMID: 38164579
[F]FDG PET/CT and [Ga]Ga-DOTATATE PET/CT are both used to predict tumor biology in neuroendocrine neoplasms. Although the presence of discordant ([F]FDG-avid/non-[Ga]Ga-DOTATATE-avid) disease predicts poor prognosis, the significance of the volume...
3.
Mileva M, Marin G, Levillain H, Artigas C, Van Bogaert C, Marin C, et al.
J Nucl Med
. 2024 Jan;
65(2):236-244.
PMID: 38164576
Our objective was to predict the outcome of peptide receptor radionuclide therapy (PRRT) using multimodality imaging and tumor dosimetry on gastroenteropancreatic neuroendocrine tumor (GEP-NET) lesions and patients. This prospective study...
4.
Danieli R, Stella M, Leube J, Tran-Gia J, Marin C, Uribe C, et al.
EJNMMI Phys
. 2023 Oct;
10(1):64.
PMID: 37853247
Background: Dosimetry after radiopharmaceutical therapy with Lu (Lu-RPT) relies on quantitative SPECT/CT imaging, for which suitable reconstruction protocols are required. In this study, we characterized for the first time the...
5.
Chan D, Hayes A, Karfis I, Conner A, OMahony L, Mileva M, et al.
Br J Cancer
. 2022 Nov;
128(4):549-555.
PMID: 36434154
Background: Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts survival by scoring uptake on dual [Ga]DOTATATE and [F]FDG PET/CT scans. We aimed...
6.
Levillain H, Burghelea M, Duran Derijckere I, Guiot T, Gulyban A, Vanderlinden B, et al.
EJNMMI Phys
. 2021 Jan;
8(1):9.
PMID: 33502601
No abstract available.
7.
Levillain H, Burghelea M, Duran Derijckere I, Guiot T, Gulyban A, Vanderlinden B, et al.
EJNMMI Phys
. 2020 Dec;
7(1):75.
PMID: 33315160
Background: The relationship between the mean absorbed dose delivered to the tumour and the outcome in liver metastases from colorectal cancer patients treated with radioembolization has already been presented in...
8.
Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, et al.
Eur J Nucl Med Mol Imaging
. 2019 Jul;
46(11):2270-2279.
PMID: 31324943
Purpose: Reported outcomes of patients with intra-hepatic cholangiocarcinoma (IH-CCA) treated with radioembolization are highly variable, which indicates differences in included patients' characteristics and/or procedure-related variables. This study aimed to identify...
9.
Marin G, Vanderlinden B, Karfis I, Guiot T, Wimana Z, Reynaert N, et al.
Phys Med
. 2018 Dec;
56:41-49.
PMID: 30527088
Purpose: Peptide receptor radionuclide therapy with Lu-DOTATATE has become a standard treatment modality in neuroendocrine tumours (NETs). No consensus has yet been reached however regarding the absorbed dose threshold for...
10.
Levillain H, Duran Derijckere I, Marin G, Guiot T, Vouche M, Reynaert N, et al.
EJNMMI Res
. 2018 Jul;
8(1):60.
PMID: 30006851
Background: The aim of this work was to confirm that post-selective internal radiation therapy (SIRT) Y-PET/CT-based dosimetry correlates with lesion metabolic response and to determine its correlation with overall survival...